Frontage Holdings (HKSE:01521) Debt-to-Asset : 0.25 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Debt-to-Asset?

Frontage Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$248 Mil. Frontage Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$885 Mil. Frontage Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was HK$4,466 Mil. Frontage Holdings's debt to asset for the quarter that ended in Dec. 2023 was 0.25.

Frontage Holdings Debt-to-Asset Historical Data

The historical data trend for Frontage Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Debt-to-Asset Chart

Frontage Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.07

0.11

0.12

0.22

0.25

Frontage Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial									0.12	0.14	0.22	0.22	0.25

Competitive Comparison of Frontage Holdings's Debt-to-Asset

For the Biotechnology subindustry, Frontage Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Frontage Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's Debt-to-Asset falls into.

Frontage Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Frontage Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(248.422	+	884.757)	/	4466.183
	=	0.25

Frontage Holdings's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(248.422	+	884.757)	/	4466.183
	=	0.25

Frontage Holdings (HKSE:01521) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Frontage Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Frontage Holdings (HKSE:01521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

FGHQF:USA

Address

700 Pennsylvania Drive, Exton, PA, USA, 19341

Website

https://www.frontagelab.com

Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines